O slideshow foi denunciado.

Cholangiocarcinoma Market

1

Compartilhar

Próximos SlideShares
Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma (HCC)
Carregando em…3
×
1 de 10
1 de 10

Cholangiocarcinoma Market

1

Compartilhar

Baixar para ler offline

Cholangiocarcinoma is a rare and heterogeneous malignant neoplasm with epithelial cell origin of biliary duct and histologic and biochemical features of cholangiocyte differentiation. The malignant tumor may arise from any portion of the bile duct i.e., from terminal ductules to the ampulla of Vater, and at the peribiliary glands.

Cholangiocarcinoma is a rare and heterogeneous malignant neoplasm with epithelial cell origin of biliary duct and histologic and biochemical features of cholangiocyte differentiation. The malignant tumor may arise from any portion of the bile duct i.e., from terminal ductules to the ampulla of Vater, and at the peribiliary glands.

Mais Conteúdo rRelacionado

Cholangiocarcinoma Market

  1. 1. CHOLANGIOCARCINOM A (CCA) Market Insights, Epidemiology, and Market Forecast- 2028
  2. 2. www.website.com 2 Cholangiocarcinoma is a rare and heterogeneous malignant neoplasm with epithelial cell origin of biliary duct and histologic and biochemical features of cholangiocyte differentiation. The malignant tumor may arise from any portion of the bile duct i.e., from terminal ductules to the ampulla of Vater, and at the peribiliary glands. ORIGIN CHOLANGIOCARCINOMA (CCA) DelveInsight © 2019 | All rights reserved It can be classified anatomically based on tumor location within the biliary tree into intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) cholangiocarcinoma subtypes. The latter two subtypes were previously grouped as extrahepatic CCA (eCCA), but are now considered distinct entities based upon differences in their tumor biology and management. BASIS Cholangiocarcinoma (CCA) is coded as intrahepatic bile duct carcinoma (C22.1), extrahepatic bile duct carcinoma (C24.0), Ampulla of Vater (C24.1), overlapping lesion of biliary tract (C24.8) or it involves both intrahepatic and extrahepatic bile ducts (C22.0-C24.1), and Biliary tract unspecified (C24.9). CLASSES
  3. 3. www.website.com Among the EU5 countries, Germany had the highest CCA incident population with 4,471 cases. EU-5 Incidence Males are more prone to Cholangiocarcinoma as compared to females among all countries. Prevalence Cholangiocarcinoma total diagnosed incident population in the 7MM was 18,470 in 2017. Diagnosed Among all the countries, the higher Cholangiocarcinoma incidence was 6,768 cases in the US in 2017. US Incidence 3 DelveInsight © 2019 | All rights reserved CCA EPIDEMIOLOGY
  4. 4. www.website.com 44www.website.com Cholangiocarcinoma market size in the 7MM* was found to USD 379.57 million in 2017 for the study period (2017-2028). 01 02 03 04 05 DelveInsight © 2019 | All rights reserved Cholangiocarcinoma Market Outlook Among 7MM* the United States accounts for the highest CCA market size in comparison with EU-5 and Japan. *7MM includes:- United States; EU 5 (Germany, France, Spain, Italy, United Kingdom); Japan. CCA market size in Germany was found to be highest with USD 82.46 million in 2017, whereas Spain has the lowest share with USD 3.69 million in 2017. Cholangiocarcinoma market size for early stage includes surgery with chemotherapy and chemoradiation therapy. The launch of various multiple-stage pipeline products will significantly revolutionize CCA market in future.
  5. 5. www.website.com 5 DelveInsight © 2019 | All rights reserved CCA Emerging Drugs and Companies Drug- Entrectinib Company- Roche 01 Drug- Pemigatinib Company- Incyte Corporation Drug- Ivosidenib Company- Agios Pharmaceuticals Drug- Regorafenib Company- Bayer 02 03 04
  6. 6. www.website.com Complete Information 6 DelveInsight © 2019 | All rights reserved For complete information on Cholangiocarcinoma Market Insights, Epidemiology & Market Forecast-2 please click the link below CLICK HERE OR Write Us At info@delveinsight.com
  7. 7. www.website.com ABOUT 7 DelveInsight © 2019 | All rights reserved About DelveInsight DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for improving their performances to stay ahead of the competitors. MISSION To provide “insights across the value chain” and helping the organization to take a prudent business decision through the use and analysis of actionable market intelligence. The mission also is to provide the most effective result and efficient service with utmost client care for maintaining a long- term relationship with them. VISION To be the most trusted market research & business consulting firm in the world; and to continue enable the Pharma & Bio-Tech companies to achieve their goals with the best strategic insight and competitive solution. The vision also is inclusive of becoming a one-stop solution provider for the entire gamut of drug development process.
  8. 8. www.website.com 8 Service Offerings by DelveInsight FORECASTING1 PIPELINE2 CONSULTING3 MARKET INTELLIGENCE4 OPPORTUNITY ASSESSMENT5 REPORT STORE6 COMPETITIVE ANALYSIS7 PHARMDELVE8 DelveInsight © 2019 | All rights reserved
  9. 9. www.website.com 9 DelveInsight © 2019 | All rights reserved Contact Us info@delveinsight.com +91-11-4568 9769 www.delveinsight.com blog/delveInsight/ twitter/delveInsight LinkedIn/delveInsight
  10. 10. www.website.com Thank You

×